If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Hypospermia is a condition in which a man has an unusually low ejaculate (or semen) volume, less than 1.5 mL. It is the opposite of hyperspermia, which is a semen volume of more than 5.5 mL. It should not be confused with oligospermia, which means low sperm count. Normal ejaculate when a man is not drained from prior sex and is suitably aroused is around 1.5–6 mL, although this varies greatly with mood, physical condition, and sexual activity. Of this, around 1% by volume is sperm cells. The U.S.-based National Institutes of Health defines hypospermia as a semen volume lower than 2 mL on at least two semen analyses. The presence of high levels of fructose (a sugar) is normal in the semen and originates almost entirely from the seminal vesicles. The seminal vesicles, which are major contributors to ejaculate volume, render semen viscous with a pH of 7.2–7.8. An acidic seminal pH (pH < 7.2) suggests damage to the seminal vesicles and an alkaline seminal pH (pH > 8) suggests prostatic involvement. In addition, low fructose may indicate problems in the prostate, while low semen pH may indicate problems related to the [seminal vesicles]. Obstruction of the seminal vesicles results in low semen volumes since they normally produce 70% of the seminal plasma.
== Personal life == In 1915, Boyd Orr married Elizabeth Pearson Callum, whom he had met as a teenager in West Kilbride. They had three children: Elizabeth Joan (born 1916), Helen Anne (born 1919) and Donald Noel (1921–1942). His son was killed on active service during the Second World War.
Serbia was liberated in the autumn of 1944, by partisan forces and the Red Army. Soon after the liberation of Belgrade on 20 October, creation of new administration was initiated. In November 1944, the Anti-fascist Assembly for the People's Liberation of Serbia was convened, affirming the policy of reconstituting Yugoslavia as a federation, with Serbia as one of its federal units. Thus was laid the foundation for the creation of the Federated State of Serbia (Serbo-Croatian Cyrillic: Федерална Држава Србија), as a federated state within new Democratic Federal Yugoslavia. The process was formalised in April 1945, when the provisional People's Assembly of Serbia was created, also appointing the first People's Government of Serbia. Two newly created regions, Autonomous Province of Vojvodina and Autonomous Region of Kosovo and Metohija, decided to merge into Serbia. On November 29 (1945), Yugoslavia was officially proclaimed as federal republic, and in January 1946, after the first Constitution of federal Yugoslavia was adopted, the Federated State of Serbia was renamed to People's Republic of Serbia (Serbo-Croatian: Народна Република Србија / Narodna Republika Srbija). In November 1946, elections for the Constitutional Assembly of Serbia were held, and in January 1947, Constitution of Serbia was adopted, reaffirming its position within Yugoslav federation, and also regulating the position of autonomous units (Vojvodina as autonomous province; Kosovo and Metohija as autonomous region). In 1953, a constitutional law was adopted, introducing further social reforms.
Sources: en.wikipedia.org
The Seven Years' War (1756–1763) was fought across all of North America, Europe, Asia, Africa, and South America. Most of the great powers of the era participated, notably including the British Empire and French Empire, but polities from many continents played important roles. As a result, some historians describe it as the first global conflict, or as a world war. Historians like Richard F. Hamilton and Holger H. Herwig created a list of eight world wars, including the two generally agreed-upon world wars, the Seven Years' War, and five others: the Nine Years' War (1689–1697), the War of the Spanish Succession (1701–1714), the War of the Austrian Succession (1740–1748), the French Revolutionary Wars (1792–1802), and the Napoleonic Wars (1803–1815). British historian John Robert Seeley dubbed all of those wars between France and Great Britain (later the UK) between 1689 and 1815 (including the American Revolutionary War from 1775 to 1783) as the Second Hundred Years' War, echoing an earlier period of conflict between France and England known as the Hundred Years' War (1337–1453). Some writers have referred to the American Revolutionary War alone as a world war. Others (like William R. Thompson or Chase-Dunn and Sokolovsky) also include the Italian Wars and Dutch wars (Dutch-Spanish and Anglo-Dutch Wars) as part of Global Wars, while classifying WW1 and WW2 as the Global German Wars, and the Coalition Wars with Wars of Louis XIV as the 2nd and 1st Global French Wars.
=== Food safety === Water activity is used in many cases as a critical control point for Hazard Analysis and Critical Control Points (HACCP) programs. Samples of the food product are periodically taken from the production area and tested to ensure water activity values are within a specified range for food quality and safety. Measurements can be made in as little as five minutes, and are made regularly in most major food production facilities. For many years, researchers tried to equate bacterial growth potential with water content. They found that the values were not universal, but specific to each food product. W. J. Scott first established that bacterial growth correlated with water activity, not water content, in 1953. It is firmly established that growth of bacteria is inhibited at specific water activity values. U.S. Food and Drug Administration (FDA) regulations for intermediate moisture foods are based on these values. Lowering the water activity of a food product should not be seen as a kill step. Studies in powdered milk show that viable cells can exist at much lower water activity values, but that they never grow. Over time, bacterial levels decline.
In 1905, J. K. Lilly oversaw a large expansion of the company, and it reached annual sales of $1 million. Following the 1906 San Francisco earthquake, the company sent much-needed medicine to support recovery efforts. Before and after World War I, the company experienced rapid growth, including expanded manufacturing facilities at its McCarty Street plant, which improved production capacity with a new Science Building (Building 14), opened in 1911, and a new capsule plant (Building 15) in 1913. In 1913, the company began construction of Lilly Biological Laboratories, a research and manufacturing plant on 150 acres near Greenfield, Indiana. After World War I, the company's expanded production facilities and introduction of new management methods set the stage for Lilly's next crucial phase—its "aggressive entry into scientific research and development." The first big step came in 1919 when Josiah Lilly hired biochemist George Henry Alexander Clowes as director of biochemical research. Clowes had extensive medical research expertise and links to the scientific research community, which led to the company's collaborations with researchers in the US and elsewhere. Clowes's first major collaboration with researchers who developed insulin at the University of Toronto significantly impacted the company's future. Lilly's success with insulin production secured the company's position as a leading research-based pharmaceutical manufacturer, allowing it to attract and hire more research scientists and to collaborate with other universities in additional medical research.
=== Discontinued === AS-601811 – oral – male pattern baldness – 5α-reductase inhibitor ATI-501 (A-201; ATI-50001) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor Brepocitinib (PF-06700841) – oral – alopecia, alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor Cioteronel (CPC-10997; Cyoctol, X-Andron) – topical – alopecia – androgen receptor antagonist Diazoxide – topical – alopecia – potassium channel opener Denileukin diftitox (Lymphirtm, Ontak, Remitoro; LY-335348; DAB389 interleukin-2) – unknown – alopecia – protein synthesis inhibitor Epristeride (Aipuliete; ONO-9302, SKF-105657) – oral – alopecia – 5α-reductase inhibitor Etrasimod (Verespiti, Velspity; APD-334, PF-07915503) – oral – alopecia areata – sphingosine 1 phosphate receptor modulator Farudodstat (ASLAN-003, LAS-186323) – oral – alopecia areata – dihydroorotate dehydrogenase inhibitor HST-001 (HSC-660) – intradermal – alopecia – intercellular signalling peptide and protein replacement Ifidancitinib (A-301, ATI-50002, ATI-502) – topical – alopecia, alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor MK-434 (MK-0434) – oral – alopecia – 5α-reductase inhibitor Naminidil (BMS-234303) – topical – alopecia – potassium channel opener NEOSH–101 – topical – alopecia – undefined mechanism of action P-1075 – unknown – alopecia – potassium channel opener Piliel – topical – alopecia – undefined mechanism of action Research programme: androgen receptor antagonists - Endoceutics (EM-4350, EM-6537) – unknown – male pattern baldness – androgen receptor antagonists Research programme: oligonucleotide therapeutics for alopecia - OliPass – unknown – alopecia – androgen receptor antagonists RU-58841 (PSK-3841, HMR-3841) – topical – alopecia – androgen receptor antagonist Secukinumab (Cosentyx) – injection – alopecia areata – IL17A protein inhibitor Setipiprant (ACT-129968, KYTH-105) – oral – alopecia – prostaglandin D2 receptor antagonist Timbetasin (thymosin β4) – unknown – alopecia – various mechanisms of action Tralokinumab (Adbry, Adtralza; CAT-354, LP-0162) – subcutaneous injection – alopecia areata – interleukin-13 inhibitor TU-2100 – topical – hair disorders – undefined mechanism of action Viprostol (CL-115347) – topical – alopecia – synthetic prostaglandin E2 analogue
Sources: en.wikipedia.org
The three substrates of this enzyme are artemisinic aldehyde, reduced nicotinamide adenine dinucleotide phosphate (NADPH), and a proton. Its products are (11R)-dihydroartemisinic aldehyde and oxidised NADP+. This enzyme is present in Artemisia annua.
Mosquitos can evolve quickly so it becomes a balancing act of killing them before the Plasmodium they carry becomes the infectious disease, but not so fast that they become resistant to the fungi. By genetically engineering fungi like Metarhizium anisopliae and Beauveria bassiana to delay the development of mosquito infectiousness the selection pressure to evolve resistance is reduced. Another strategy is to add proteins to the fungi that block transmission of malaria or remove the Plasmodium altogether. Agaricus bisporus the common white button mushroom, has been gene edited to resist browning, giving it a longer shelf life. The process used CRISPR to knock out a gene that encodes polyphenol oxidase. As it didn't introduce any foreign DNA into the organism it was not deemed to be regulated under existing GMO frameworks and as such is the first CRISPR-edited organism to be approved for release. This has intensified debates as to whether gene-edited organisms should be considered genetically modified organisms and how they should be regulated.
== Relationship to electroceuticals == In 2012, the global pharmaceutical company GlaxoSmithKline announced an initiative in bioelectric medicine in which the autonomic nervous system's impact on the immune system and inflammatory disease might be treated through electrical stimulation rather than pharmaceutical agents. The company's first investment in 2013 involved a small startup company, SetPoint Medical, which was developing neurostimulators to address inflammatory autoimmune disorders such as rheumatoid arthritis. Ultimately, the electroceuticals quest aims to find the electro-neural signature of disease and, at a cellular level, in real time, play back the more normal electro-signature to help maintain the neural signature in the normal state. Unlike preceding neuromodulation therapy methods, the approach would not involve electrical leads stimulating large nerves or spinal cords or brain centers. It might involve methods that are emerging within the neuromodulation family of therapies, such as optogenetics or some new nanotechnology. Disease states and conditions that have been discussed as targets for future electroceutical therapy include diabetes, infertility, obesity, rheumatoid arthritis, and autoimmune disorders.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.